Trial Profile
PHARMACOKINETICS (PK) OF EDOXABAN, A NOVEL ORAL ANTICOAGULANT (NOAC), WHEN DOSED ALONE OR FOLLOWING SWITCHING FROM DABIGATRAN OR RIVAROXABAN.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Oct 2016
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary) ; Dabigatran etexilate; Rivaroxaban
- Indications Embolism; Stroke; Venous thromboembolism
- Focus Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 16 Aug 2016 Results of this and two other studies published in the British Journal of Clinical Pharmacology
- 23 Nov 2015 Results published in the Clinical Drug Investigation
- 07 Apr 2014 New trial record